Hospira gains rights to commercialize Kiadis Pharma's ATIR in Europe, Africa and Asia-Pacific

Netherlands-based Kiadis Pharma has entered into a licensing agreement with the USA’s specialty pharma company Hospira, (NYSE: HSP) to develop and commercialize Kiadis Pharma's ATIR, a personalized hematology product designed for blood cancer patients in need of allogeneic bone marrow transplantation who cannot locate a matched donor. The product will enable a mismatched family member to act as donor and is being developed to reduce transplant related mortality caused by infections and graft-versus-host disease.

Under the terms of the deal, Hospira is granted exclusive marketing rights to ATIR for Europe, the Middle East, Africa, Australia, Japan and parts of Asia. Kiadis maintains all rights to the product for the rest of the world. Financial terms include an undisclosed upfront payment and partial funding of the ATIR registration clinical trial currently ongoing in Europe and North America. Upon successful development and commercialization of ATIR in the European market, Kiadis can receive additional milestone payments and is entitled to royalties on product sales.

"We are very pleased to have Hospira as a partner bringing extensive pharmaceutical development expertise into the ATIR development program. Hospira's commitment to commercialize ATIR will ultimately accelerate making this lifesaving product available for patients," says Manja Bouman, chief executive of Kiadis Pharma.